Legend Biotech: Carvykti Makes Billions, But The Profits Are Elusive

CARVYKTI quarterly sales reached $710 million, while Legend’s high expenses continue to constrain recurring profitability. Q2 results showed improving operating leverage, with collaboration revenue growing faster than associated costs. The author rates LEGN a cautious buy, citing commercial growth potential but limited margin of safety.

Analysis

The key underwriting issue is the gap between CARVYKTI’s product-level sales and the portion of economics that ultimately accrues to Legend. Collaboration terms and revenue recognition determine how much commercial growth converts into LEGN cash flow; product sales alone are not a proxy for Legend’s revenue or margins. Improving operating leverage is encouraging, but it needs to persist after separating commercial costs from R&D and other corporate expenses.

Over the next 1–3 months, the most useful catalyst is the next report’s bridge from collaboration revenue to associated costs, alongside cash burn and any guidance changes. Over 6–18 months, treatment capacity, manufacturing throughput, and competition from Bristol Myers Squibb’s Abecma and other modalities will determine whether growth translates into durable economics. Safety, manufacturing, or reimbursement setbacks could disrupt the ramp; stronger reported sales without improving Legend-level contribution would also weaken the thesis.

The contrarian risk is treating rapid product growth as proof of near-term profitability. With no valuation, cash-flow, or collaboration-term detail here, the margin of safety cannot be assessed. This is a conditional operating-leverage thesis, not a clean read-through from CARVYKTI sales.

Key Decisions for Investors

• Keep LEGN on a watchlist rather than adding solely on product-sales momentum. Before initiating, verify the collaboration revenue share and recognition mechanics, the cost categories included in the leverage claim, and the latest cash/burn runway.
• If those checks support improving contribution economics, consider a staged long after the next earnings release confirms leverage across another quarter; size modestly given execution and competitive risk.
• Falsify the thesis if collaboration revenue stops outpacing the associated costs for two consecutive reports, cash burn worsens materially, or management reduces commercial expectations. Reassess promptly after any safety, manufacturing, or reimbursement setback.
• Track CARVYKTI growth relative to Legend-recognized revenue and cash generation—not just product sales—and monitor competitive progress from Abecma for evidence of pricing, access, or demand pressure.